%0 Journal Article %T Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer %A Jeong, Byeong-Ho %A Um, Sang-Won %J Journal of Thoracic Disease %D 2018 %B 2018 %9 %! Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer %K %X Osimertinib (Tagrisso, AstraZeneca) is a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and irreversibly inhibits EGFR-TKI sensitizing mutations and the T790M mutation; the drug exhibits lower-level activity against wild-type EGFR (1). Recently, the AME Lung Cancer Collaborative Group summarized the current role of osimertinib and made recommendations as to how osimertinib could, %U https://jtd.amegroups.org/article/view/26164 %V 11 %N 1 %P 39-41 %@ 2077-6624